Moleculin Biotech reports Q1 EPS ($2.02) vs. ($4.13) last year

As of March 31, the company had cash and cash equivalents of $16.8M and believes that this cash is sufficient to meet its projected operating requirements, which includes the company’s current Phase 1B/2 clinical programs and preparations for future clinical trials, into Q4 2024. “We recently hosted a virtual AML Clinical Day featuring renowned KOLs, Dr. Martin Tallman and Dr. Michael Andreeff. It was great to hear their support of and thoughts on Annamycin’s recent developments in AML. You can hear that discussion here. Combined with the encouraging Annamycin data demonstrated to date and the positive feedback from the KOLs, we continue to believe that our results in 2nd line subjects fill a significant unmet need. We believe this is supported by the exceptional CRc rate demonstrated by AnnAraC in 2nd line patients, which substantially exceeds the performance reported by any drug currently approved in the U.S. for use in 2nd line AML. We believe we are well-positioned for a highly productive End of Phase 2 meeting with FDA to discuss our planned pivotal study of Annamycin for AML,” commented CEO Walter Klemp.